FB301 for a Lactobacillus-dominant vaginal microbiome in a mock FET cycle
Official title: A Randomized, Double-blind, Three Arm, Multi-center Phase 2 Study to Investigate the Molecular Efficacy and Safety of FB301/Chlorhexidine Compared With FB301/Sham and Placebo/Sham in a Mock FET Cycle in Female Participants 18-45 Years of Age With Asymptomatic Vaginal Molecular Dysbiosis Planning to Undergo a Frozen Embryo Transfer (FET) Cycle
Run by Freya Biosciences ApS · NCT07453069 · Data updated 2026-11-12
This trial tests whether FB301 can help shift the vaginal bacteria toward Lactobacillus dominance in women with vaginal dysbiosis during a pretend embryo transfer cycle.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 45 Years |
| Sex | Women only |
| Enrollment | 30 (estimated) |
| Sponsor | Freya Biosciences ApS Industry-sponsored |
| Drugs / interventions | chemotherapy |
| Locations | 4 sites (Wichita, Kansas and 3 other locations) |
| Status | Recruiting |
| Started | July 22, 2026 |
| Main results expected | October 31, 2026 |
| Study ends | September 30, 2027 |
| Registry record updated | October 15, 2026 |
| Trial ID | NCT07453069 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Women aged 18–45 with a history of a prior failed FET and a molecularly defined vaginal dysbiosis who are planning a subsequent FET.
✕Probably not a fit
Individuals without Lactobacillus-dominant dysbiosis or those unlikely to pursue a subsequent FET may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a Phase 2, randomized, blind study evaluating FB301 versus placebo in premenopausal women with a prior failed FET and a defined vaginal dysbiosis. Participants receive a 15-day FB301 or placebo during a mock FET cycle after a vaginal cleansing, with a second arm using a chlorhexidine cleanse before FB301. The primary outcome is the proportion of participants achieving a Lactobacillus-dominant vaginal microbiome after therapy. Secondary aims include pregnancy-related biochemical outcomes and safety/tolerability in the context of a simulated embryo transfer process. The study will monitor participants through the mock cycle and, if appropriate, into a subsequent actual FET cycle.
Why it matters
Potential benefit: If successful, FB301 could help promote a healthier vaginal microbiome that may improve chances in future embryo transfer attempts.
How similar studies have gone: Previous research has linked Lactobacillus-dominant vaginal profiles with better reproductive outcomes in FET, supporting exploration of microbiome-modifying therapies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria:
1. Able to understand the study and sign a consent form.
2. Is a woman aged 18 to 45 years.
3. Still has regular menstrual periods (pre-menopausal).
4. Has had at least one previous frozen embryo transfer (FET) that did not result in pregnancy within the past 3 years, and this was not due to either male infertility or blocked /damaged fallopian tubes.
5. Willing to take part in mock frozen embryo transfer (FET) cycle and is considered medically suitable to subsequently have a frozen embryo transfer (FET) using one good-quality embryo (grade 3BB or higher).
6. Willing to have only one embryo transferred during the study cycle.
7. A vaginal swab taken at the first study visit shows a specific vaginal microbiome imbalance required for this study (vaginal molecular dysbiosis).
8. An ultrasound scan shows no problems with uterus or pelvis that would prevent pregnancy or greatly reduce the chance of pregnancy.
9. Recent fertility blood tests show FSH less than 12 IU/L (within the last 6 months)
10. Recent fertility blood tests show AMH greater than 1 ng/mL (at the time of oocyte retrieval).
11. Body mass index (BMI) is between 18 and 42 kg/m².
12. From the first study treatment until the mock FET cycle, agrees to:
* Avoid vaginal intercourse or use condoms (without spermicide or lubricant),
* Avoid swimming or hot tubs,
* Avoid using tampons, menstrual cups, sex toys, vaginal cleansers, lubricants, or other vaginal products unless approved by the study team.
13. Willing to answer questions about sexual and reproductive activity during the study.
14. Willing to provide vaginal swab samples at the clinic.
15. Willing to receive the first study treatment in the clinic and use the study treatment at home as instructed.
16. Screening blood tests are negative for hepatitis B, hepatitis C, HIV, and syphilis.
17. Willing to attend all study visits and follow-up assessments and provide information about pregnancy and newborn health outcomes.
Exclusion Criteria:
1. History of five or more failed frozen embryo transfers (FET) in the past 5 years.
2. Have a condition that weakens the immune system (such as uncontrolled diabetes, active cancer, or an organ transplant).
3. Currently taking medications that suppress the immune system (such as systemic steroids, biologics, chemotherapy, or transplant medications).
4. Is already pregnant before completing the mock FET cycle.
5. Test positive for a sexually transmitted infection (such as chlamydia, gonorrhea, Mycoplasma genitalium, or Trichomonas vaginalis).
6. Current vaginal yeast infection that requires treatment.
7. Cannot safely take the hormone medications required for a frozen embryo transfer (such as estradiol or progesterone).
8. Use of intravaginal progesterone gels or solutions.
9. Needs regular antibiotics or are likely to require antibiotics during the study.
10. Has taken oral, injectable, or vaginal antibiotics within 30 days before screening.
11. History of gynecological cancer or other significant gynecological condition that would make participation unsafe.
12. Has a medical condition that would make participation unsafe or difficult.
13. Has an unstable medical or psychiatric condition that could make it difficult to follow study requirements.
14. Has any other condition that could interfere with participation.
Where it's running
-
Cypress Medical Research Centre
Wichita, Kansas, United States Recruiting -
REACH Fertility
Charlotte, North Carolina, United States Recruiting -
Delta Hy Research LLC / Advanced Fertility Texas
Houston, Texas, United States Recruiting -
Boston IVF
Waltham, Massachusetts, United States Not yet recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Improving vaginal microbiota in premenopausal women with dysbiosis
This study is testing a new vaginal gel to see if it can help premenopausal women with imbalanced vaginal bacteria and prevent future infections.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.